Sugi Predict

Sugi Predict / Compounds / SCHEMBL1699443

SCHEMBL1699443

SCHEMBL1699443

CC(=O)Cc1ccc(F)cc1F

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 1/20 0.51
▸ IDO1 P14902 2/20 0.50
▸ AGXT P21549 2/20 0.50
▸ RIPK1 Q13546 2/20 0.46
▸ MAPK8 P45983 1/20 0.46
▸ CES2 O00748 2/20 0.45
▸ CES1 P23141 2/20 0.45
▸ P2RX7 Q99572 2/20 0.43
▸ SIGMAR1 Q99720 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14263434 0.84 RIPK1 (0.47) MAOBRIPK1MAPK8CES2CES1
SCHEMBL434355 0.83 IDO1 (0.48) MAOBIDO1AGXTRIPK1MAPK8
SCHEMBL1288294 0.83 IDO1 (0.48) MAOBIDO1AGXTRIPK1MAPK8
SCHEMBL16866563 0.82 CHRNA7 (0.49) MAOBALDH1A1TDP1
SCHEMBL14232910 0.82 P2RX7 (0.45) MAOBP2RX7ALDH1A1
SCHEMBL10862456 0.82 P2RX7 (0.45) MAOBP2RX7SMN1; SMN2
SCHEMBL503325 0.82 TSHR (0.53) MAOBIDO1AGXTRIPK1MAPK8
SCHEMBL29459931 0.82 TSHR (0.53) MAOBIDO1AGXTRIPK1MAPK8
SCHEMBL23869529 0.81 RIPK1 (0.48) MAOBIDO1AGXTRIPK1MAPK8
SCHEMBL21222818 0.81 MAOB (0.53) MAOBIDO1AGXTRIPK1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040077895-A1 Process for the preparation of strobilurin intermediates WADITSCHATKA RUDOLF (CH) 2004-04-22 — — US claimed
JP-2002531540-A — — 2002-09-24 — — JP claimed
EP-1137627-A1 PROCESS FOR THE PREPARATION OF STROBILURIN INTERMEDIATES Bayer Aktiengesellschaft (DE) 2001-10-04 — — EP claimed
WO-2000034229-A1 PROCESS FOR THE PREPARATION OF STROBILURIN INTERMEDIATES BAYER AKTIENGESELLSCHAFT (DE) 2000-06-15 — — WO claimed
US-20220332718-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS GENENTECH, INC. (US) 2022-10-20 — — US disclosed
CN-108473498-B Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators 豪夫迈·罗氏有限公司 2021-11-02 — — CN disclosed
US-10988478-B1 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators GENENTECH, INC. (US) 2021-04-27 — — US disclosed
EP-3394066-A2 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS H. Hoffnabb-La Roche Ag (CH) 2018-10-31 — — EP disclosed
US-20180298015-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS GENENTECH, INC. (US) 2018-10-18 — — US disclosed
CN-105431414-B The 4 round rings formamides as nematicide 先正达参股股份有限公司 2018-06-15 — — CN disclosed
WO-2018055133-A1 MICROBIOCIDAL TETRAZOLONE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2018-03-29 — — WO disclosed
WO-2017108723-A2 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2017-06-29 — — WO disclosed
WO-2006089060-A1 FUNGICIDAL PYRAZINE DERIVATIVES E.I. DUPONT DE NEMOURS AND COMPANY (US) 2006-08-24 — — WO disclosed
EP-1641756-A1 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR MERCK SHARP & DOHME LTD. (GB) 2006-04-05 — — EP disclosed
WO-2004101518-A1 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR MERCK SHARP & DOHME LIMITED (GB) 2004-11-25 — — WO disclosed
US-20040077895-A1 Process for the preparation of strobilurin intermediates WADITSCHATKA RUDOLF (CH) 2004-04-22 — — US disclosed
US-6664422-B1 Process for the preparation of strobilurin intermediates BAYER AKTIENGESELLSCHAFT (DE) 2003-12-16 — — US disclosed
EP-1137627-A1 PROCESS FOR THE PREPARATION OF STROBILURIN INTERMEDIATES Bayer Aktiengesellschaft (DE) 2001-10-04 — — EP disclosed
US-6248765-B1 ANTIINFLAMMATORY AGENTS; HYPOTENSIVE AGENTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (FR) 2001-06-19 — — US disclosed
WO-2000034229-A1 PROCESS FOR THE PREPARATION OF STROBILURIN INTERMEDIATES BAYER AKTIENGESELLSCHAFT (DE) 2000-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077895-A1 Process for the preparation of strobilurin intermediates TET1, CYP1B1, STS MAOB 457/4885IDO1 260/4885AGXT 556/4885
US-20180298015-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS IRAK1, IRAK4, IRAK2 MAOB 4248/4885IDO1 1382/4885AGXT 3815/4885
US-20220332718-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS IRAK1, IRAK4, IRAK2 MAOB 4054/4885IDO1 1052/4885AGXT 4330/4885
US-10988478-B1 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators IRAK1, IRAK4, IRAK2 MAOB 4248/4885IDO1 1382/4885AGXT 3815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.